The efficacy and safety of a combination of tinidazole and thioconazole in the treatment of vaginal infections

  • Autores: Torshin I.Y.1,2, Apolikhina I.A3,4, Baranov I.I5,6, Tapilskaya N.I5,6, Savicheva A.M7, Gromova O.A1,2
  • Afiliações:
    1. Federal Research Center of Informatics and Management, Russian Academy of Sciences
    2. Moscow State University
    3. Acad. V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
    4. I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
    5. D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology
    6. Saint Petersburg State Pediatric Medical University, Ministry of Health of the Russian Federation
    7. V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
  • Edição: Nº 4 (2020)
  • Páginas: 214-223
  • Seção: Articles
  • URL: https://journals.eco-vector.com/0300-9092/article/view/248973
  • DOI: https://doi.org/10.18565/aig.2020.4.214-222
  • ID: 248973

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The paper gives the results from a meta-analysis of clinical trials using Gainomax (its standard dose is thioconazole 100 mg, tinidazole 150 mg as a suppository or cream) for the therapy of vulvovaginal candidiasis (VVC), bacterial vaginosis (BV), and trichomaniasis (TM). The meta-analysis included 4 clinical trials (covering 209patients). The patients’ mean age was 35±7years (95% CI, 18-52); all the patients used Gainomax suppositories/cream at the standard dose for 7 days or double dose for 3 days. Gainomax therapy substantially increased the chances of clinical cure of BV (by 20 times; OR 20.4; 95% CI 9.5-43.6), microbiological cure of BV (by 16 times; OR 15.5; 95% CI 7.6-31.5), cures of VVC (by 21 times; OR 21.0; 95% CI 8.8-50.2) and TM (by 29 times; OR 28.8; 95% CI 7.4-111.8). Analyzing individual clinical symptoms revealed associations between drug use and a statistically significant reduction in pathological vaginal discharge (by 25 times; OR 0.04; 95% CI 0.02-0.08), inflammation symptoms (by 33 times; OR 0.03; 95% CI 0.02-0.06), and reddening (by 11 times; OR 0.09; 95% CI 0.06-0.15) during treatment. Only one of the four trials included in the meta-analysis described side effects (in 3 out of209patients in the entire sample), no side effects were noted in the remaining trials. Thus, the results of this meta-analysis confirm the high efficacy and safety of the intravaginal use of a combination of tinidazole and thioconazole for the treatment of BV, VVC, and TM.

Texto integral

Acesso é fechado

Sobre autores

I. Torshin

Federal Research Center of Informatics and Management, Russian Academy of Sciences; Moscow State University

Email: tiy135@ccas.ru
Cand. Phys.-Math. Sci., Cand. Chem. Sci. Institute of Pharmacoinformatics, Federal Research Center of Informatics and Management, Russian Academy of Sciences; Senior Researcher, Big Data Storage and Analysis Center, Moscow State University 42, Vavilov St., Moscow 119333, Russia

I. Apolikhina

Acad. V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

Email: i_apolikhina@oparina4.ru
MD, Head, Department of Aesthetic Gynecology and Rehabilitation, Professor, Department of Obstetrics, Gynecology, Perinatology, and Reproductology, Institute of Professional Education 4, Academician Oparin St., Moscow 117997, Russia

I. Baranov

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology; Saint Petersburg State Pediatric Medical University, Ministry of Health of the Russian Federation

Email: i_baranov@oparina4.ru
MD, Professor, Head, Department for Scientific and Educational Programs, Scientific Organizational Support Service 4, Academician Oparin St., Moscow 117997, Russia

N. Tapilskaya

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology; Saint Petersburg State Pediatric Medical University, Ministry of Health of the Russian Federation

Email: savitcheva@mail.ru
DM; Professor, Leading Researcher, Department of Assisted Reproductive Technologies, D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology; Professor, Department of Obstetrics and Gynecology 3, Mendeleevskaya Line, Saint Petersburg 199034, Russia

A. Savicheva

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: i_baranov@oparina4.ru
MD; Professor, Honored Scientist of the Russian Federation; Head, Department of Medical Microbiology, D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology; Head, Department of Clinical Laboratory Diagnosis, Faculty for Postgraduate and Advanced Professional Education 199034, Russia; 2, Litovskaya St., Saint Petersburg 194100, Russia

O. Gromova

Federal Research Center of Informatics and Management, Russian Academy of Sciences; Moscow State University

Email: unesco.gromova@gmail.com
MD; Professor, Leading Researcher, Big Data Storage and Analysis Center 42, Vavilov St., Moscow 119333, Russia

Bibliografia

  1. Громова О.А, Торшин И.Ю., Гарасько Е.В. Физиологические и молекулярные механизмы топического воздействия аскорбиновой кислоты на вагинальную флору. Гинекология. 2010; 12(5): 9-15
  2. Громова О.А., Торшин И.Ю., Гарасько Е.А. Молекулярные механизмы разрушения бактериальных пленок при топическом применении аскорбиновой кислоты. Гинекология. 2010; 12(6): 12-7
  3. Plourd D.M. Practical guide to diagnosing and treating vaginitis. Medscape Womens Health. 1997; 2(2): 2.
  4. Карапетян Т.Э., Муравьева В.В., Анкирская А.С., Любасовская Л.А., Припутневич Т.В. Возможности лечения оппортунистических инфекций влагалища во врея беременности. Гинекология. 2017; 19(6): 11-5.
  5. Вадикова Н.С., Кира Е.Ф. Эффективная и безопасная монотерапия интра-вагинальными суппозиториями Гайномакс и Вагинорм С. Медицинский вестник Юга России. 2014; 2: 30-3
  6. Henderson J.T., Neilson W., Wilson A.B., Jevons S. Tioconazole in the treatment of vaginal candidiasis. An international clinical research program. Gynakol. Rundsch. 1983; 23(Suppl. 1): 42-60.
  7. Kukner S., Ergin T., Cigek N., Ugur M., Ye§ilyurt H., Gokmen O. Treatment of vaginitis. Int. J. Gynaecol. Obstet. 1996; 52(1): 43-7. https://dx.doi. org/10.1016/0020-7292(95)02531-6.
  8. Torshin I.Yu. Bioinformatics in the post-genomic era: physiology and medicine. New York, USA: Nova Biomedical Books; 2007.
  9. Торшин И.Ю., Лиманова О.А., Громова О.А., Тетруашвили Н.К., Коденцова В.М., Малявская С.И., Гришина Т.Р., Калачева А.Г., Мозговая Е.В., Захарова И.Н., Галустян А.Н., Семенов В.А., Громов А.Н., Лебедев А.В., Керимкулова Н.В., Лапочкина Н.П., Никифорова Н.В., Назаренко О.А., Вогачева Т.Е., Федотова Л.Э., Гоголева И. В., Жид о моров Н.Ю., Фролова Д.Е., Рубашкина А.Н., Серов В.Н. Метрический анализ данных по взаимосвязям между показателями микронутриентной обеспеченности и состоянием здоровья женщин 18-45 лет. Медицинский алфавит. 2018; 2(21): 10-20.
  10. Cagayan S., Bravo S.L., Fallarme A. Randomized, single-blind, one-centre trial comparing the efficacy, safety and acceptability of 3-day versus 7-day treatment of GYNOMAX® (150 mg tinidazole/100 mg tioconazole) vaginal ovules in vaginitis treatment. In: The 3rd Asia Pacific Congress on Controversies in Obstetrics Gynecology & Infertility. Beijing, China. November 12-15, 2009.
  11. Farah C.H., D’Elia E., Trabulsi L.R. Use of tinidazole/tioconazole combination in the treatment of vaginal infections caused by Trichomonas, Gardnerella vaginalis or Candida albicans. J. Bras. Ginecol. 1987; 97(1-2): 43-7.
  12. Leitzke G., Focchi J., Reitzfeld G. et al. Open non-comparative study of Tioconazole/ Tinidazole vaginal cream in the treatment of vaginal infections due to Trichomonas vaginalis, Candida albicans and or Gardnerella vaginalis. J. Bras. Ginecol. 1989; 99(7): 303-7.
  13. Каткова Н.Ю., Гусева О.И., Качалина О.В., Сошников А.В., Малышев В.В., Заславская М.И., Сергеева А.В. Лечение вагинитов при беременности. Акушерство и гинекология. 2020;4:190-194.
  14. Волков В.Г., Захарова Т.В. Оптимизация предоперационной подготовки женщин с цервикальными неоплазиями высокой степени, РМЖ. Мать и дитя. 2019; 2(3): 243-6
  15. Peixoto F., Camargos A., Duarte G., Linhares I., Bahamondes L., Petracco A. Efficacy and tolerance of metronidazole and miconazole nitrate in treatment of vaginitis. Int. J. Gynaecol. Obstet. 2008; 102(3): 287-92. https://dx.doi. org/10.1016/j.ijgo.2008.04.014.
  16. Cagayan S., Bravo S., Fall arm e A., Sison O., Gabaldon M. Randomized, single-blinded comparison of efficacy, safety and tolerability of metronidazole 750mg-miconazole 200mg vaginal suppository vs. metronidazole 500mg-nystatin 100,000 IU vaginal suppository in the treatment of bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis, and mixed vaginal infections. Philippine Journal of Obstetrics and Gynecology(PJOG). 2015; 39(3): 14-21.
  17. Zion S.R., Crum A.J. Mindsets Matter: A new framework for harnessing the placebo effect in modern medicine. Int. Rev. Neurobiol. 2018; 138: 137-60. https://dx.doi.org/10.1016/bs.irn.2018.02.002.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2020